Cargando…

Engineered Viruses as Vaccine Platforms

Many viruses have been investigated for the development of genetic vaccines and the ideal ones must be endowed with many properties, such as the quality and the quantity of the immunological response induced against the encoded antigens, safety and production on a large scale basis. Viral based vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Folgori, Antonella, Capone, Stefania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120934/
http://dx.doi.org/10.1007/978-94-007-4543-8_4
_version_ 1783515086333149184
author Folgori, Antonella
Capone, Stefania
author_facet Folgori, Antonella
Capone, Stefania
author_sort Folgori, Antonella
collection PubMed
description Many viruses have been investigated for the development of genetic vaccines and the ideal ones must be endowed with many properties, such as the quality and the quantity of the immunological response induced against the encoded antigens, safety and production on a large scale basis. Viral based vaccines must also deal with the potential problem of the pre-existing antivector immunity. Several viral vaccine vectors have emerged to date, all of them having relative advantages and limits depending on the proposed application. Recent successes reflect diverse improvements such as development of new adenovirus serotypes and prime-boost regimes. This chapter describes the features of four viral vector systems based on poxviruses, adenoviruses, alphaviruses and lentiviruses and recent results following their use with a particular emphasis on clinical research, highlighting the challenges and successes.
format Online
Article
Text
id pubmed-7120934
institution National Center for Biotechnology Information
language English
publishDate 2012
record_format MEDLINE/PubMed
spelling pubmed-71209342020-04-06 Engineered Viruses as Vaccine Platforms Folgori, Antonella Capone, Stefania Innovation in Vaccinology Article Many viruses have been investigated for the development of genetic vaccines and the ideal ones must be endowed with many properties, such as the quality and the quantity of the immunological response induced against the encoded antigens, safety and production on a large scale basis. Viral based vaccines must also deal with the potential problem of the pre-existing antivector immunity. Several viral vaccine vectors have emerged to date, all of them having relative advantages and limits depending on the proposed application. Recent successes reflect diverse improvements such as development of new adenovirus serotypes and prime-boost regimes. This chapter describes the features of four viral vector systems based on poxviruses, adenoviruses, alphaviruses and lentiviruses and recent results following their use with a particular emphasis on clinical research, highlighting the challenges and successes. 2012-03-29 /pmc/articles/PMC7120934/ http://dx.doi.org/10.1007/978-94-007-4543-8_4 Text en © Springer Science+Business Media Dordrecht 2012 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Folgori, Antonella
Capone, Stefania
Engineered Viruses as Vaccine Platforms
title Engineered Viruses as Vaccine Platforms
title_full Engineered Viruses as Vaccine Platforms
title_fullStr Engineered Viruses as Vaccine Platforms
title_full_unstemmed Engineered Viruses as Vaccine Platforms
title_short Engineered Viruses as Vaccine Platforms
title_sort engineered viruses as vaccine platforms
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120934/
http://dx.doi.org/10.1007/978-94-007-4543-8_4
work_keys_str_mv AT folgoriantonella engineeredvirusesasvaccineplatforms
AT caponestefania engineeredvirusesasvaccineplatforms